Sanofi (SNY) said Monday the European Commission has approved its drug, Teizeild, to delay the onset of stage 3 type 1 diabetes in patients aged eight and older with stage 2 type 1 diabetes.
The company said the decision follows a recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use to approve the drug.
The drugmaker said the approval is based on a phase 2 study that showed that Teizield delayed progression to stage 3 type 1 diabetes by a median of two years compared with placebo.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments